Zydus Lifesciences Limited has informed the Exchange regarding a press release dated March 12, 2025, titled "Zynext Ventures invests in Illexcor Therapeutics to advance novel oral therapy for sickle cell disease".
Press Release Mar 12 2025
Filed with NSE · · 3 pages · English
Summary by 6ix AI
This investment highlights Zydus's commitment to addressing significant unmet medical needs in healthcare. The press release includes statements from key executives emphasizing the strategic importance of this partnership. The document serves to inform investors and the stock exchange about this significant development.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Mar 10 2025
- Press Release Mar 05 2025
- Press Release Mar 04 2025
- Press Release Feb 26 2025
- Press Release Feb 22 2025
Later from Zydus Lifesciences
- Press Release Mar 14 2025
- Press Release Mar 16 2025
- Press Release Mar 18 2025
- Press Release Apr 11 2025
- Press Release Apr 16 2025
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences